NASDAQ:ALECAlector Stock Price, Forecast & News

Alector's stock was trading at $24.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALEC shares have decreased by 37.9% and is now trading at $15.48.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alector.

Alector is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Alector.

Alector Inc (NASDAQ:ALEC) posted its earnings results on Wednesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.10. The company had revenue of $7.17 million for the quarter, compared to the consensus estimate of $10.60 million. Alector had a negative net margin of 556.70% and a negative return on equity of 48.29%.
View Alector's earnings history.

8 equities research analysts have issued 12-month target prices for Alector's stock. Their forecasts range from $28.00 to $41.00. On average, they expect Alector's share price to reach $32.80 in the next twelve months. This suggests a possible upside of 111.9% from the stock's current price.
View analysts' price targets for Alector.

News articles about ALEC stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alector earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Alector.

Alector saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,760,000 shares, an increase of 11.6% from the June 15th total of 5,160,000 shares. Based on an average trading volume of 492,100 shares, the short-interest ratio is presently 11.7 days. Currently, 11.1% of the company's shares are sold short.
View Alector's Current Options Chain.

Some companies that are related to Alector include Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Sorrento Therapeutics (SRNE), Immunovant (IMVT) and SpringWorks Therapeutics (SWTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Cisco Systems (CSCO), Harpoon Therapeutics (HARP), Johnson & Johnson (JNJ), Kaleido Biosciences (KLDO) and AT&T (T).

(ALEC) raised $177 million in an IPO on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO.

Alector trades on the NASDAQ under the ticker symbol "ALEC."

Alector's stock is owned by a number of institutional and retail investors. Top institutional investors include First Trust Advisors LP (0.18%), ProShare Advisors LLC (0.02%), SG Americas Securities LLC (0.02%) and Strs Ohio (0.01%). Company insiders that own Alector stock include Calvin Yu, David M Wehner, Orbimed Advisors Llc, Robert King, Robert Paul, Sabah Oney and Terrance Mcguire.
View institutional ownership trends for Alector.

ALEC stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Strs Ohio, ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Alector stock in the last two years include David M Wehner, and Orbimed Advisors Llc.
View insider buying and selling activity for Alector.

Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALEC stock can currently be purchased for approximately $15.48.

Alector has a market capitalization of $1.22 billion and generates $21.22 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Alector employs 91 workers across the globe.

The official website for Alector is www.alector.com.

Alector's mailing address is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]